

For Qualified Investors in Switzerland, or Professional Investors or Eligible Counterparties as defined by the relevant laws

## UBAM - DR. EHRHARDT GERMAN EQUITY

### Capturing the best investment opportunities in Europe's strongest economy

UBAM - Dr. Ehrhardt German Equity is a high-conviction German equity fund. It uses a combination of top-down and bottom-up research and sophisticated market timing and monetary analysis as it seeks to outperform the market.

#### Key points

- ◆ *German stocks are cheap relative to their international competitors*
- ◆ *High-conviction German equity fund based on three layers of complementary analysis*
- ◆ *Strong outperformance of the benchmark since inception*
- ◆ *High-quality, on-the-ground investment team*

#### Investment case

The German economy is the strongest in Europe, with prudent fiscal policy, a healthy trade balance and no real estate bubble. With exports accounting for almost half of GDP, Germany benefits from any weakness in the euro as well as from growth in Asia, a major trading partner. Its stock market is generally cheaper than that of other major economies, and German companies have made considerable progress in terms of optimising cost structures and margins over the past few years.

#### Fund concept

UBAM - Dr. Ehrhardt German Equity invests mainly in blue chips, with an emphasis on companies with strong balance sheets and proven management teams. The fund's composition can differ significantly from that of the benchmark and it may use cash or derivatives to preserve value in falling markets.

The investment process is based on Dr. Ehrhardt's proprietary "FMM approach", which combines fundamental research with analysis of monetary and market sentiment indicators. This technique has delivered strong relative returns in both up and down markets since the fund's inception.

#### Relative performance versus the DAX




Sources: Bloomberg, 05.2018  
Past performance is not indicative of future results.



## Investment process

- ◆ Investment process driven by three layers of analysis which combine to produce high-conviction top-down and bottom-up exposures that are unconstrained by the benchmark
  - ▶ Fundamental analysis concentrates on company research to identify firms with a healthy balance sheet and low debt
  - ▶ Monetary analysis determines the liquidity supply, which can have a profound impact on demand in the stock market
  - ▶ Market timing analysis aims to identify market inefficiencies and when investors have begun to ignore fundamentals
- ◆ Particular attention is paid to the risk of loss – either in terms of corporate valuations or market momentum
- ◆ All investment decisions are based on in-house analysis, without the use of third-party research, ensuring independence and rapid implementation of ideas



## Investment guidelines

- ◆ Benchmark: DAX Index
- ◆ Benchmark-aware rather than benchmark-constrained
- ◆ Holdings: around 35–55 stocks

## Investment team

- ◆ Fund managed by Dr. Jens Ehrhardt Kapital AG, the biggest independent German asset management firm founded in 1974
- ◆ The manager, Dr. Jens Ehrhardt, is supported by a team of 19 investment professionals who conduct independent research based on the firm's proprietary modelling techniques
- ◆ Assets under management and advisory services amounted to EUR 30 mn as at the end of May 2018

## Main Risks



SRRI relates to the IC EUR share class LU0181358846 as of 31.01.2019. This indicator represents the annual historical volatility of the fund. Risk category reflects level of risk and return profile: 1 lowest; 2 low; 3 limited; 4 average/moderate; 5 high; 6 very high; 7 highest risk. Historical data such as that used to calculate the synthetic indicator cannot be considered as a reliable indication of the fund's future risk profile. The risk category associated with the fund is not guaranteed and may change over time.

## General information

Fund name	UBAM
Sub-fund name	UBAM - Dr. Ehrhardt German Equity
Legal form of the fund	Luxembourg-incorporated umbrella SICAV, UCITS
Launch date	18 May 1998
Bid/offer price	NAV
Currency	EUR (USD/CHF/GBP/SEK)
Subscription/redemption	Daily
Management fee	A: 1.50% / I: 1.00%
Management company	UBP Asset Management (Europe) S.A.

Investment manager	DR. Jens Ehrhardt Kapital AG
Administrator	CACEIS Bank Luxembourg S.A.
Registrar/transfer agent	CACEIS Bank Luxembourg S.A.
Custodian	BNP Paribas Securities Services Luxembourg
Auditor	Deloitte Audit S.à.r.l., Luxembourg
Countries where distribution is authorised	AT, BE, CH, DE, ES, FI, FR, IT, LU, NL, NO, PT, SE, SG, UK
ISIN	AC EUR: LU0087798301 IC EUR: LU0181358846

## Disclaimer

This is a marketing document and is intended for informational and/or marketing purposes only. This document is confidential and intended only for the use of the person(s) to whom it was delivered. It may not be reproduced (in whole or in part) or delivered, given, sent or in any other way made accessible to any other person without the prior written approval of Union Bancaire Privée, UBP SA or any entity of the UBP Group ("UBP"). This document reflects the opinion of UBP as of the date of issue. This document is for distribution only to persons who are Qualified Investors in Switzerland, or Professional Clients, Eligible Counterparties or an equivalent category of investors as defined by the relevant laws (all such persons together being referred to as "relevant persons"). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. It is not intended for distribution, publication, or use, in whole or in part, in any jurisdiction where such distribution, publication, or use would be unlawful, nor is it directed at any person at whom or entity at which it would be unlawful to direct such a document. In particular, this document may not be distributed in the United States of America and/or to US persons (including US citizens residing outside the United States of America). This document has not been produced by UBP's financial analysts and is not to be considered financial research. It is not subject to any guidelines on financial research and independence of financial analysis. Reasonable efforts have been made to ensure that the content of this document is based on information and data obtained from reliable sources. However, UBP has not verified the information from third sources in this document and does not guarantee its accuracy or completeness. UBP makes no representations, provides no warranty, and gives no undertaking, express or implied, regarding any of the information, projections or opinions contained herein, nor does it accept any liability whatsoever for any errors, omissions or misstatements. The information contained herein is subject to change without prior notice. UBP gives no undertaking to update this document or to correct any inaccuracies in it which may become apparent. This document may refer to the past performance of investment interests. Past performance is not a guide to current or future results. The value of investment interests can fall as well as rise. Any capital invested may be at risk and investors may not get back some or all of their original capital. Any performance data included in this document does not take into account fees, commissions, and expenses charged on issuance and redemption of securities, nor any taxes that may be levied. Changes in exchange rates may cause increases or decreases in investors' returns. All statements other than statements of historical fact in this document are "forward-looking statements". Forward-looking statements do not guarantee future performances. The financial projections included in this document do not represent forecasts or budgets, but are purely illustrative examples based on a series of current expectations and assumptions which may not eventuate. The actual performance, results, financial condition and prospects of an investment interest may differ materially from those expressed or implied by the forward-looking statements in this document as the projected or targeted returns are inherently subject to significant economic, market and other uncertainties that may adversely affect performance. UBP also disclaims any obligation to update forward-looking statements, as a result of new information, future events or otherwise. None of the contents of this document should be construed as advice or any form of recommendation to purchase or sell any securities or funds. This document does not replace a prospectus or any other legal documents, which can be obtained free of charge from the registered office of the fund they relate to, or from UBP. The opinions herein do not take into account individual investors' circumstances, objectives, or needs. Each investor must make his/her own independent decision regarding any securities or financial instruments mentioned herein and should independently determine the merits or suitability of any investment. In addition, the tax treatment of any investment in the fund(s) mentioned herein depends on each individual investor's circumstances and may be subject to change in the future. Investors are invited to carefully read the risk warnings and the regulations set out in the prospectus or other legal documents and to seek professional financial, legal and tax advice. This document should not be deemed an offer nor a solicitation to buy, subscribe to, or sell any currency, funds, products, or financial instruments, to make any investment, or to participate in any particular trading strategy in any jurisdiction where such an offer or solicitation would not be authorised, or to any person to whom it would be unlawful to make such an offer or solicitation. Telephone calls to the telephone number stated in this document may be recorded. UBP will assume that by calling this number you consent to such recording. UBP is authorised and regulated in Switzerland by the Swiss Financial Market Supervisory Authority and is authorised in the United Kingdom by the Prudential Regulation Authority. UBP is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Any subscriptions not based on the funds' latest prospectuses, KIDs, annual or semi-annual reports or other relevant legal document shall not be acceptable. The latest prospectus, articles of association, KID and annual and semi-annual reports of the funds presented herein (the "Funds' Legal Documents") may be obtained free of charge from Union Bancaire Privée, UBP SA, 96-98 rue du Rhône, P.O. Box 1320, 1211 Geneva 1 ("UBP"). The Funds' Legal Documents may also be obtained free of charge from UBP Asset Management (Europe) S.A., 287-289 route d'Arlon, 1150 Luxembourg, Grand Duchy of Luxembourg, and from Union Bancaire Gestion Institutionnelle (France) SAS, 116 avenue des Champs-Élysées, 75008 Paris, France. The Swiss representative and paying agent of the foreign funds mentioned herein is UBP. The Funds' Legal Documents may be obtained free of charge from UBP, as indicated above.